CorneaGen Inc.

CorneaGen Inc. is a Seattle-based firm specializing in innovative solutions for eye health, particularly in the field of corneal transplantation and tissue engineering. Founded in 2016 and headquartered in Seattle, US, CorneaGen Inc. focuses on advancing corneal tissue solutions.

The company has executed 3 deals, with its latest being a SERIES B funding round in October 2019 where it raised USD 37. 00 mn. The funding was co-led by Falcon Vision and Flying L Partners, along with participation from Petrichor Healthcare Capital Management. Monty Montoya is the founder of the company, having previously founded other ventures which contribute to his experience in this sector.

CorneaGen Inc. specializes in delivering innovative solutions tailored for eye care, particularly focusing on corneal transplantation technologies. Their core offerings include a range of preserved corneal tissues that meet specific patient needs, enhancing the functionality of eye surgeries. These products cater to various sectors within the healthcare industry, particularly ophthalmology, and have been positively received by hospitals and eye care specialists.

The company's revenue model is primarily based on B2B sales, where hospitals and clinics procure corneal tissues directly from CorneaGen Inc. This structured approach enables effective partnerships and a steady revenue stream, reflecting the value of their specialized offerings. The company also engages in collaborations that further enhance its market presence across healthcare channels. CorneaGen Inc.

is actively developing new product lines aimed at expanding its offerings in corneal transplant technologies. The company aims to launch these new solutions by 2023, targeting both domestic and international markets for further reach. The recent SERIES B funding of USD 37. 00 mn will support these initiatives, including advancements in research and development, as well as expansion into key geographic regions to increase accessibility to their products.